Fennec Pharmaceuticals Cioffi acquires 156 shares

Q: How many FENC shares did Chief Strategy Officer Christiana Marie Cioffi acquire?

Christiana Marie Cioffi acquired 156 common shares on October 31, 2026. Her reported direct holdings after the transaction were 28,902 common shares.

The shares came from an award made on March 28, 2025, before their restrictions were released.

Available on EDGAR 11/02/2026 - 04:49 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:48 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on October 31, 2026, when previously awarded shares were released from restriction. Her reported direct holdings after the transaction were 28,902 common shares. This was a release of previously awarded shares, rather than a separately described market purchase.

Insider Trade Summary

Grant/Award: 156 shares

Grant/Award 1 txn

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common shares ^F1	156	$0.00	$0.00

Holdings After Transaction: Common shares — 28,902 shares (Direct)

Holdings Before and After: Common shares, 28,746 to 28,902 shares (Direct)

Footnotes (1)

F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 156 common shares Direct holdings after transaction: 28,902 common shares Original award date: March 28, 2025

3 metrics

Shares acquired 156 common shares Released from restriction on October 31, 2026

Direct holdings after transaction 28,902 common shares Reported after the October 31, 2026 transaction

Original award date March 28, 2025 Date of the award from which the shares were released from restriction

Key Terms

shares released from restriction, shares awarded

2 terms

shares released from restriction financial

"shares released from restriction from shares awarded"

shares awarded financial

"shares awarded 3/28/2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FENC shares did Chief Strategy Officer Christiana Marie Cioffi acquire?

Christiana Marie Cioffi acquired 156 common shares on October 31, 2026. Her reported direct holdings after the transaction were 28,902 common shares.

When were the released FENC shares originally awarded?

The 156 common shares released from restriction came from shares awarded on March 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last)

(First)

(Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK

NORTH CAROLINA

27709

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares⁽¹⁾	10/31/2026		A		156	A	$0	28,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Christiana Cioffi	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR